{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:27:05Z","timestamp":1793320025126,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.schres.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T21:43:59Z","timestamp":1741556639000},"page":"140-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Impact of long-acting injectable antipsychotics in early psychosis: An umbrella review"],"prefix":"10.1016","volume":"277","author":[{"given":"Marie","family":"Etienne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Verdoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2025.03.002_bb0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","article-title":"Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"139","author":"Alvarez-Jimenez","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.03.002_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.03.002_bb0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int. J. Evid. Based Healthc."},{"key":"10.1016\/j.schres.2025.03.002_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","article-title":"Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophr. Heidelb. Ger."},{"key":"10.1016\/j.schres.2025.03.002_bb0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry Off","volume":"21","author":"Correll","year":"2022","journal-title":"J. World Psychiatr. Assoc. WPA"},{"key":"10.1016\/j.schres.2025.03.002_bb0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2025.03.002_bb0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/eip.12027","article-title":"Long-acting injectable antipsychotics in early psychosis: a literature review","volume":"7","author":"Emsley","year":"2013","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.schres.2025.03.002_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.38358","article-title":"Comparative effectiveness of antipsychotics in patients with schizophrenia Spectrum disorder","volume":"7","author":"Hamina","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.schres.2025.03.002_bb0045","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jclinepi.2013.01.012","article-title":"Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry","volume":"66","author":"Kane","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.schres.2025.03.002_bb0050","first-page":"289","article-title":"Depot antipsychotics: where do we stand? Ann. Clin. Psychiatry off","volume":"28","author":"Khan","year":"2016","journal-title":"J. Am. Acad. Clin. Psychiatr."},{"key":"10.1016\/j.schres.2025.03.002_bb0055","article-title":"Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons","volume":"2012","author":"Kim","year":"2012","journal-title":"Schizophr. Res. Treat."},{"key":"10.1016\/j.schres.2025.03.002_bb0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2045125312464106","article-title":"Patients\u2019 and clinicians\u2019 attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis","volume":"3","author":"Kirschner","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.schres.2025.03.002_bb0065","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.psychres.2016.10.053","article-title":"Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: a systematic review and meta-analysis of randomized controlled trials","volume":"246","author":"Kishi","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2025.03.002_bb0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs Oral antipsychotics for relapse prevention in schizophrenia: a Meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2025.03.002_bb0075","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/schbul\/sbx090","article-title":"Effectiveness of long-acting injectable vs Oral antipsychotics in patients with schizophrenia: a Meta-analysis of prospective and retrospective cohort studies","volume":"44","author":"Kishimoto","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2025.03.002_bb0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre\u2013post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2025.03.002_bb0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia\u2014a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.03.002_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267808","article-title":"Long-acting injectable antipsychotics for early psychosis: a comprehensive systematic review","volume":"17","author":"Lian","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2025.03.002_bb0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/eip.13202","article-title":"Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: a systematic review and meta-analysis","volume":"16","author":"Lian","year":"2022","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.schres.2025.03.002_bb0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2016.11.010","article-title":"Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies","volume":"183","author":"Ostuzzi","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.03.002_bb0105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","article-title":"Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network Meta-analysis","volume":"178","author":"Ostuzzi","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.03.002_bb0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.64719\/pb.4123","article-title":"Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations","volume":"40","author":"Parellada","year":"2007","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2025.03.002_bb0115","first-page":"361","article-title":"Comparative efficacy and safety of long-acting injectable and Oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and Meta-analysis. Clin. Psychopharmacol","volume":"16","author":"Park","year":"2018","journal-title":"Neurosci. Off. Sci. J. Korean Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2025.03.002_bb0120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00406-016-0740-3","article-title":"Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP)","volume":"267","author":"Pelayo-Ter\u00e1n","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2025.03.002_bb0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","article-title":"Systematic review finds overlapping reviews were not mentioned in every other overview","volume":"67","author":"Pieper","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.schres.2025.03.002_bb0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/YIC.0000000000000249","article-title":"Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review","volume":"34","author":"Salgueiro","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2025.03.002_bb0135","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2025.03.002_bb0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","article-title":"Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies","volume":"27","author":"Solmi","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2025.03.002_bb0145","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1176\/appi.ajp.21121189","article-title":"Effectiveness of antipsychotic use for reducing risk of work disability: results from a within-subject analysis of a swedish national cohort of 21,551 patients with first-episode nonaffective psychosis","volume":"179","author":"Solmi","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.03.002_bb0150","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/0706743719847193","article-title":"Long-acting antipsychotics: the QAAPAPLE algorithm review","volume":"64","author":"Stip","year":"2019","journal-title":"Can. J Psychiatr. Rev. Can. Psychiatr."},{"key":"10.1016\/j.schres.2025.03.002_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2804","article-title":"Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms","volume":"36","author":"Takeuchi","year":"2021","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2025.03.002_bb0160","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/0004867412470010","article-title":"Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review","volume":"47","author":"Taylor","year":"2013","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.03.002_bb0165","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a Nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2025.03.002_bb0170","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/acps.12722","article-title":"Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study","volume":"135","author":"Verdoux","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2025.03.002_bb0175","doi-asserted-by":"crossref","unstructured":"Vita, G., Tavella, A., Ostuzzi, G., Tedeschi, F., De Prisco, M., Segarra, R., Solmi, M., Barbui, C., Correll, C.U., 2024. Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis. Ther. Adv. Psychopharmacol. 14, 20451253241257062. doi:https:\/\/doi.org\/10.1177\/20451253241257062.","DOI":"10.1177\/20451253241257062"},{"key":"10.1016\/j.schres.2025.03.002_bb0180","article-title":"Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review","volume":"2012","author":"Zhornitsky","year":"2012","journal-title":"Schizophr. Res. Treat."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:03:06Z","timestamp":1774530186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996425000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":36,"alternative-id":["S0920996425000659"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2025.03.002","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of long-acting injectable antipsychotics in early psychosis: An umbrella review","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}